October 10, 2017
Longevity Biotech Granted U.S. Patent Covering Hybridtide Platform Technology for Stabilized Peptide Therapeutics
Longevity Biotech, Inc. (LBT) is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,782,454 covering the company's Hybridtide® platform technology.